5HT 2a受容体T102Cポリモルフィズムと統合失調症について

GIP mediates the incretin effect and glucose tolerance by dual actions on α cells and β cells.

Science advances·2021

Glucose and lipid effects of the ileal apical sodium-dependent bile acid transporter inhibitor GSK2330672: double-blind randomized trials with type 2 diabetes subjects taking metformin.

Diabetes, obesity & metabolism·2016

Therapeutic potential of Takeda-G-protein-receptor-5 (TGR5) agonists. Hope or hype?

Diabetes, obesity & metabolism·2016

GSK2374697, a long duration glucagon-like peptide-1 (GLP-1) receptor agonist, reduces postprandial circulating endogenous total GLP-1 and peptide YY in healthy subjects.

Diabetes, obesity & metabolism·2015

GSK2374697, a novel albumin-binding domain antibody (AlbudAb), extends systemic exposure of exendin-4: first study in humans--PK/PD and safety.

Clinical pharmacology and therapeutics·2014

Prediction of weight loss and regain following dietary, lifestyle, and pharmacologic intervention.

Clinical pharmacology and therapeutics·2012

1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial.

Lancet (London, England)·2026

Multidomain lifestyle intervention for the prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial.

Lancet (London, England)·2026

Advancing the relevance of clinical trials for older patients.

Lancet (London, England)·2026

Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial.

Lancet (London, England)·2026

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.

Lancet (London, England)·2026

Children in all policies: lessons from a global collaboration to promote the health and wellbeing of children and future generations.

Lancet (London, England)·2026

Distinct neural alterations in schizophrenia and autism: a task-based functional neuroimaging meta-analysis of social cognition and emotion processing.

Scientific reports·2026

Prevalence, Structure and Barriers of Academic Pharmacy Fellowships: A Survey of Program Directors.

American journal of pharmaceutical education·2026

A real-time exploration of the affect regulation hypothesis surrounding substance use.

Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors·2026

Expression and experience domains of negative symptoms in relation to social functioning in patients with schizophrenia: Results from a commonality analysis.

Schizophrenia research. Cognition·2026

Is everyone looking at me? The perception of direct gaze as a potential cognitive marker in social anxiety and its moderation by emotional expression.

Journal of affective disorders·2026

Social fear memory as a framework for understanding social defeat stress and psychopathology.

Neuroscience and biobehavioral reviews·2026

関連する実験動画

5HT 2a受容体T102Cポリモルフィズムと統合失調症について

関連する概念動画

GIP mediates the incretin effect and glucose tolerance by dual actions on α cells and β cells.

Glucose and lipid effects of the ileal apical sodium-dependent bile acid transporter inhibitor GSK2330672: double-blind randomized trials with type 2 diabetes subjects taking metformin.

Therapeutic potential of Takeda-G-protein-receptor-5 (TGR5) agonists. Hope or hype?

GSK2374697, a long duration glucagon-like peptide-1 (GLP-1) receptor agonist, reduces postprandial circulating endogenous total GLP-1 and peptide YY in healthy subjects.

GSK2374697, a novel albumin-binding domain antibody (AlbudAb), extends systemic exposure of exendin-4: first study in humans--PK/PD and safety.

Prediction of weight loss and regain following dietary, lifestyle, and pharmacologic intervention.

1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial.

Multidomain lifestyle intervention for the prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial.

Advancing the relevance of clinical trials for older patients.

Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial.

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.

Children in all policies: lessons from a global collaboration to promote the health and wellbeing of children and future generations.

Distinct neural alterations in schizophrenia and autism: a task-based functional neuroimaging meta-analysis of social cognition and emotion processing.

Prevalence, Structure and Barriers of Academic Pharmacy Fellowships: A Survey of Program Directors.

A real-time exploration of the affect regulation hypothesis surrounding substance use.

Expression and experience domains of negative symptoms in relation to social functioning in patients with schizophrenia: Results from a commonality analysis.

Is everyone looking at me? The perception of direct gaze as a potential cognitive marker in social anxiety and its moderation by emotional expression.

Social fear memory as a framework for understanding social defeat stress and psychopathology.

関連する実験動画

5HT 2a受容体T102Cポリモルフィズムと統合失調症について

関連する概念動画

関連記事